Abstract: A test method for a variable speed limit (VSL) strategy in a mixed traffic flow considering driver compliance is provided. A road scenario is built, and multiple mixed traffic flows formed by human-driven vehicles (HDVs) and connected and automated vehicles (CAVs) are set, which vary in CAV penetration rate. The VSL strategy is established, and a speed limit of an upstream of the bottleneck area is calculated based on the VSL strategy. A HDV compliance is established, and in combination with the speed limit, the HDV drivers are classified, and a proportion of the HDV drivers in individual types in the road scenario is determined. Based on a traffic flow scenario in which the HDV drivers and CAV drivers are located, indicator data reflecting traffic capacity is calculated. A test system for performing the test method is further provided.

Abstract: Methods, systems, apparatuses, and computer-readable storage mediums described herein are directed to determining and recommending an optimal compute resource configuration for a cloud-based resource (e.g., a server, a virtual machine, etc.) for migrating a customer to the cloud. The embodiments described herein utilize a statistically robust approach that makes recommendations that are more flexible (elastic) and account for the full distribution of the amount of resource usage. Such an approach is utilized to develop a personalized rank of relevant recommendations to a customer. To determine which compute resource configuration to recommend to the customer, the customer's usage profile is matched to a set of customers that have already migrated to the cloud. The compute resource configuration that reaches the performance most similar to the performance of the configurations utilized by customers in the matched set is recommended to the user.

Abstract: Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases.

Abstract: Disclosed are a compound as shown in formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, cocrystal or deuterated compound thereof, or a pharmaceutical composition containing same, and the use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases, wherein the definition of each group in formula (I) is as defined in the description.

Abstract: Disclosed in the present application are a signal continuous coverage method, device and apparatus for a target area, and an antenna system.

Abstract: The invention provides a positive electrode material, a preparation method thereof, and an electrochemical device. The positive electrode material is a secondary particle formed by the aggregation of primary particles. The secondary particle contains a cavity structure inside. Based on the positive correlation characteristics between the content of an A element in the positive electrode material particles and the cavity ratio, by introducing an appropriate proportion of the A element when the positive electrode material precursor is formed, the accompanying cavity structure formed inside the precursor is at an appropriate cavity ratio, in order to ensure that the positive electrode material may buffer the volume strain during the charge and discharge process through the internal appropriate proportion of the cavity structure, and alleviate the rupture phenomenon of the secondary particle during the cycle, thereby improving the cycle life and volume energy density of the positive battery.

Abstract: A smooth cooperative lane change control method for multi-connected and autonomous vehicles (CAVs), including: acquiring vehicle information of a lane-changing vehicle M and four surrounding vehicles A, B, C and D; constructing uncontrolled-vehicle and controlled-vehicle motion state prediction models; according to the motion state prediction models, predicting motion states of the lane-changing vehicle M, and the vehicles A, B, C and D; constructing an upper-layer optimization model to calculate an optimal control value and an optimized motion state of the lane-changing vehicle M and an optimal control value of the vehicle A; constructing a lower-layer optimization model to calculate an optimal control value of the vehicle D; and controlling the lane-changing vehicle M, the vehicle A and the vehicle D to run according to a corresponding optimal control value.

Abstract: A compound of formula (I) and a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition containing same, and the use thereof as an AAK1 inhibitor in the preparation of a drug for treating related diseases.

Abstract: A computing system automatically manages error reports. Each error report specifies an error that occurred within a subsystem of the computing system. A received error report is added into a root cause grouping. Each root cause grouping contains error reports having error types traceable to a same root cause. A deployment time at which the subsystem corresponding to the error report was deployed within the computing system is determined. A severity score for the root cause grouping is generated as a function of the deployment time. The severity score inversely correlates to a time period length between the deployment time and the occurrence time of the error. The root cause grouping is assigned to a ranked error container of a plurality of ranked error containers based on the generated severity score. Each ranked error container contains root cause groupings having severity scores within a specified score range.

Abstract: Provided herein are compositions and methods to prevent and to treat ?-synucleinopathies for research and therapeutic purposes. In particular, provided herein are compositions, methods, kits and uses for inhibition of pathological phosphorylation and spread of ?-synuclein in the central nervous system as therapeutic targets of neurodegenerative disorders including dementia with Lewy bodies and Parkinson's disease dementia.

Abstract: A heterojunction solar cell and a preparation method therefor. The heterojunction solar cell comprises: a semiconductor substrate layer; and a back composite transparent conductive film located on one side of the semiconductor substrate layer. The back surface composite transparent conductive film comprises: a first back surface transparent conductive film; and a second back transparent conductive film located on the side surface of the first back transparent conductive film facing away from the semiconductor substrate layer. Both the first back transparent conductive film and the second back transparent conductive film are doped with group III heavy atoms, and the concentration of the group III heavy atoms in the second back transparent conductive film is less than that of the group III heavy atoms in the first back transparent conductive film.

Abstract: A heterojunction cell and a method for preparing same. The heterojunction cell comprises: a semiconductor substrate layer; and an intrinsic semiconductor composite layer, wherein the intrinsic semiconductor composite layer is located on the surface of at least one side of the semiconductor substrate layer, and the intrinsic semiconductor composite layer comprises: a bottom intrinsic layer; and a wide-band-gap intrinsic layer, which is located on the surface of the side of the bottom intrinsic layer that is away from the semiconductor substrate layer, the band gap of the wide-band-gap intrinsic layer being greater than the band gap of the bottom intrinsic layer. The band gap of a wide-band-gap intrinsic layer is larger, and when sunlight irradiates a heterojunction cell, photons, the energy of which is less than that of the band gap of the wide-band-gap intrinsic layer, cannot be subjected to parasitic absorption.

Abstract: The present disclosure belongs to the technical field of lubricating material preparation, and specifically relates to a halloysite nanotube (HNT)-encapsulated ionic liquid (IL) microcapsule, a self-lubricating fiber textile composite, and a preparation method and use thereof. In the present disclosure, the preparation method includes the following steps: dispersing a HNT and an alkali metal salt of a saturated fatty acid in water, dispersing a resulting inner surface-modified HNT and an IL in an organic solvent, injecting the IL into the HNT in the mixed dispersion under vacuumizing to obtain an IL-filled HNT, and encapsulating a resulting IL-filled HNT at a tube end with an encapsulating material to obtain the HNT-encapsulated IL microcapsule.

Abstract: The present invention relates to a compound as represented by formula (I) and a stereoisomer, solvate, deuterated compound or pharmaceutically acceptable salt or pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating/preventing ER-mediated diseases, wherein each group in formula (I) is as defined in the description.

Abstract: The present invention relates to a device, system and method for pulsatility detection.

Abstract: The present disclosure belongs to the technical field of lubricating material preparation, and specifically relates to a halloysite nanotube (HNT)-encapsulated ionic liquid (IL) microcapsule, a self-lubricating fiber textile composite, and a preparation method and use thereof. In the present disclosure, the preparation method includes the following steps: dispersing a HNT and an alkali metal salt of a saturated fatty acid in water, dispersing a resulting inner surface-modified HNT and an IL in an organic solvent, injecting the IL into the HNT in the mixed dispersion under vacuumizing to obtain an IL-filled HNT, and encapsulating a resulting IL-filled HNT at a tube end with an encapsulating material to obtain the HNT-encapsulated IL microcapsule.

Abstract: The present disclosure relates to fluorescent biosensors and methods of use thereof. In particular, provided herein is a genetically encoded fluorescent indicator (GEFI) comprising a circular-permuted fluorescent protein (cpFP) and an inhibitory molecule bound to the cpFP. In the basal state, the inhibitory molecule prevents fluorescence from the circular-permuted fluorescent protein. Upon conformational change and/or cleavage of the bond between the inhibitory molecule and the cpFP, the cpFP is disinhibited, thereby permitting fluorescence from the cpFP. The biosensors described herein may be used in methods for detecting a variety of cell-signaling events.

Abstract: Provided are a compound of formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic thereof, or a pharmaceutical composition comprising same, and use thereof as a ketohexokinase inhibitor in the preparation of drugs for treating related diseases. Each group in formula (I) is as defined in the description.

Abstract: Disclosed is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a drug for treating diseases including obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.

Abstract: Provided is a process for producing a tinned copper wire. The process comprises subjecting a copper wire sequentially to activation treatment, a first hot tinning treatment, a first cooling, a second hot tinning treatment, and a second cooling to obtain a tinned copper wire. The first hot tinning treatment is carried out at a first temperature and the second hot tinning treatment is carried out at a second temperature. The first temperature is higher than the second temperature. The first temperature is at least 38° C. higher than the melting point of tin. The second temperature is at least 8° C. higher than the melting point of tin.